Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform
Curapath and Cristal Therapeutics signed a co-exclusive license for the CliCr® bioconjugation platform on November 26, 2025.
Under the agreement, Curapath is the exclusive contract manufacturer (CDMO) to apply CliCr® for the delivery of nucleic acids.
The partnership enables Curapath to offer advanced bioconjugation solutions for nucleic acid therapeutics, supporting drug innovators in gene therapy and related fields.
The CliCr® platform is designed to enhance the efficiency and versatility of bioconjugation, particularly for challenging payloads such as nucleic acids.